// App-Quantinova.ai

7513 : Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Researchers

Presenter

  • Johannes Dll

Principal Investigators

  • Kami J. Maddocks

  • Eva Gonzalez-Barca

  • Wojciech Jurczak

  • Anna Marina Liberati

  • Ale Obr

  • Gianluca Gaidano

  • Pau Abrisqueta

  • Marc Andr

  • Martin H. Dreyling

  • Tobias Menne

  • Maren Dirnberger-Hertweck

  • Johannes Weirather

  • Sumeet Vijay Ambarkhane

  • Gilles A. Salles

Medical Centers

  • Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg, Germany

  • Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH, Department of Hematology, Institut Catalá d’Oncologia (ICO), Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain

  • Clinical Oncology Clinic, Maria Sklodowska-Curie National Research Institute of Oncology, Cracov, Poland

  • Università degli Studi di Perugia,Azienda Ospedaliera Santa Maria di Terni,Terni,Italy

  • Department of Hemato-Oncology, Palacký University and University Hospital, Olomouc, Czech Republic, Division of Hematology, Department of Translational Medicine, University of Piemonte Orientale Amedeo Avogadro, Novara, Italy

  • Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain

  • Department of Hematology, Universite catholique de Louvain, CHU UCL Namur, Yvoir, Belgium

  • Ludwig-Maximilians-University, University Hospital, Munich, Germany

  • Department of Biochemistry, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

  • MorphoSys AG, Planegg, Germany

  • Hématologie, Hospices Civils de Lyon and Université de Lyon, Lyon, France

Locations

  • Germany

  • Spain

  • Poland

  • Italy

  • Belgium

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Lenalidomide

  • Tafasitamab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02399085

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved